214 related articles for article (PubMed ID: 10447932)
1. Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent.
Jung D; Hilmes C; Knuth A; Jaeger E; Huber C; Seliger B
Scand J Immunol; 1999 Sep; 50(3):242-9. PubMed ID: 10447932
[TBL] [Abstract][Full Text] [Related]
2. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
[TBL] [Abstract][Full Text] [Related]
3. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production.
Soos JM; Ashley TA; Morrow J; Patarroyo JC; Szente BE; Zamvil SS
Int Immunol; 1999 Jul; 11(7):1169-79. PubMed ID: 10383950
[TBL] [Abstract][Full Text] [Related]
5. B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells.
Bain C; Merrouche Y; Puisieux I; Duc A; Colombo MP; Favrot M
Int J Cancer; 1996 Sep; 67(6):769-76. PubMed ID: 8824547
[TBL] [Abstract][Full Text] [Related]
6. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.
Antonia SJ; Seigne JD
World J Urol; 2000 Apr; 18(2):157-63. PubMed ID: 10854153
[TBL] [Abstract][Full Text] [Related]
7. Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens.
Yi-qun Z; Joost van Neerven RJ; Kasran A; de Boer M; Ceuppens JL
Int Immunol; 1996 Jan; 8(1):37-44. PubMed ID: 8671587
[TBL] [Abstract][Full Text] [Related]
8. Induction of antigen-specific T cells by allogeneic CD80 transfected human carcinoma cells.
Meyer GC; Moebius U; Rudy W; Batrla R; Meuer SC; Wallwiener D; Gückel B
Adv Exp Med Biol; 1998; 451():195-202. PubMed ID: 10026872
[No Abstract] [Full Text] [Related]
9. Interleukin-10 inhibits the immune stimulatory potential of melanoma cells retrovirally transduced with human B7.1 or B7.2.
Geertsen R; Yue FY; Pavlovic J; Laine E; Dummer R
Adv Exp Med Biol; 1998; 451():179-88. PubMed ID: 10026870
[No Abstract] [Full Text] [Related]
10. A T cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70.
Nieland JD; Kruisbeek AM
Int Immunol; 1995 Nov; 7(11):1827-38. PubMed ID: 8580081
[TBL] [Abstract][Full Text] [Related]
11. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10.
Dummer R; Yue FY; Pavlovic J; Geertsen R; Döhring C; Moelling K; Burg G
Br J Cancer; 1998 May; 77(9):1413-9. PubMed ID: 9652756
[TBL] [Abstract][Full Text] [Related]
12. Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma.
Rudy W; Gückel B; Siebels M; Lindauer M; Meuer SC; Moebius U
Int Immunol; 1997 Jun; 9(6):853-60. PubMed ID: 9199968
[TBL] [Abstract][Full Text] [Related]
13. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro.
Batten P; McCormack AM; Page CS; Yacoub MH; Rose ML
Transplantation; 1999 Nov; 68(10):1552-60. PubMed ID: 10589954
[TBL] [Abstract][Full Text] [Related]
14. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.
Pettit SJ; Ali S; O'Flaherty E; Griffiths TR; Neal DE; Kirby JA
Clin Exp Immunol; 1999 Apr; 116(1):48-56. PubMed ID: 10209504
[TBL] [Abstract][Full Text] [Related]
15. Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity.
Vermeiren J; Ceuppens JL; Haegel-Kronenberger H; De Boer M; Boon L; Van Gool SW
Clin Exp Immunol; 2004 Feb; 135(2):253-8. PubMed ID: 14738453
[TBL] [Abstract][Full Text] [Related]
16. Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination.
Kerkmann-Tucek A; Banat GA; Cochlovius B; Zöller M
Int J Cancer; 1998 Jul; 77(1):114-22. PubMed ID: 9639402
[TBL] [Abstract][Full Text] [Related]
17. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity.
Barcy S; Wettendorff M; Leo O; Urbain J; Kruger M; Ceuppens JL; de Boer M
Int Immunol; 1995 Feb; 7(2):179-89. PubMed ID: 7537534
[TBL] [Abstract][Full Text] [Related]
18. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.
Dunnion DJ; Cywinski AL; Tucker VC; Murray AK; Rickinson AB; Coulie P; Browning MJ
Immunology; 1999 Dec; 98(4):541-50. PubMed ID: 10594686
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation.
Quandt D; Jasinski-Bergner S; Müller U; Schulze B; Seliger B
J Transl Med; 2014 May; 12():151. PubMed ID: 24885059
[TBL] [Abstract][Full Text] [Related]
20. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
